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ther evidence for the efficacy and safety of maintenance 
treatment with opioid agonists. In the long term, the num-
ber of opioid-free patients is low and most patients are more 
or less continuously under opioid maintenance therapy. Fur-
ther implications are discussed.  © 2017 S. Karger AG, Basel 
 Introduction 
 Opioid use disorders are defined by a problematic pat-
tern of substance use that leads to clinically significant 
impairment in different areas. ICD-10  [1] and DSM-IV 
 [2] define opioid dependence as a chronic medical disor-
der characterised by a cluster of somatic, psychological 
and behavioural symptoms. Both classification systems 
follow a categorical approach and list 11 symptoms for 
opioid use disorders. The recently published DSM-5  [3] 
uses a dimensional approach and also lists 11 symptoms 
for substance use disorders, including opioid use. The 
presence of 6 or more symptoms indicates a severe use 
disorder; 4–5 are moderate and 2–3 are mild ones.
 Opioid dependence is a chronic relapsing disorder 
with a significant mortality rate  [4–6] and a high rate of 
psychiatric and somatic comorbidities. The non-medical 
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 Abstract 
 Background: In many countries, the opioid agonists, bu-
prenorphine and methadone, are licensed for maintenance 
treatment of opioid dependence. Many short-term studies 
have been performed, but little is known about long-term 
effects. Therefore, this study described over 6 years (1) mor-
tality, retention and abstinence rates and (2) changes in con-
comitant drug use and somatic and mental health.  Methods: 
A prevalence sample of  n = 2,694 maintenance patients, re-
cruited from a nationally representative sample of  n = 223 
substitution doctors, was evaluated in a 6-year prospective-
longitudinal naturalistic study. At 72 months,  n = 1,624 pa-
tients were assessed for outcome; 1,147 had full outcome 
data, 346 primary outcome data and 131 had died; 660 indi-
viduals were lost to follow-up.  Results: The 6-year retention 
rate was 76.6%; the average mortality rate was 1.1%. During 
follow-up, 9.4% of patients became “abstinent” and 1.9% 
were referred for drug-free addiction treatment. Concomi-
tant drug use decreased and somatic health status and social 
parameters improved.  Conclusions: The study provides fur-
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use of opioids, including heroin, represents a significant 
public health problem. Epidemiological studies indicate 
that the worldwide prevalence of opioid use disorders is 
about 0.4% in individuals aged 15–64 and that there are 
15.5 million opioid-dependent people worldwide  [7] . 
 Epidemiological data suggest that in the European Union, 
prevalence rates for opioid consumption have declined in 
recent years  [8] ; however, there are still about 1.3 million 
individuals with problematic opioid use in the EU, with a 
prevalence of about 0.4%. The drugs of choice have shift-
ed somewhat from heroin towards other opioids, includ-
ing methadone, buprenorphine and fentanyl  [8] . 
 In the United States, some 3.7 million individuals have 
used heroin at least once in their lives and 750,000–
1,000,000 individuals are currently heroin dependent  [9, 
10] . The World Health Organization (WHO) estimates 
that the burden of harm from opioid use is 11.2 million 
disability-adjusted life years (DALYs)  [11] and the  Global 
Burden of Disease study estimates that the burden of 
harm from opioid dependence is 9.2 million DALYs  [5, 
12] . In addition, the United States in particular has an 
epidemic of opioid prescription drug use and has record-
ed multiple deaths associated with an overdose of opioid 
pain killers, including many accidental poisonings in 
children  [13, 14] .
 Opioid maintenance treatment is a well-established 
first-line approach for opioid dependence. Methadone, 
buprenorphine or the combination of buprenorphine 
and naloxone is frequently used  [15–19] . Methadone and 
buprenorphine have proven efficacy and are widely used 
in opioid dependence [review by  16, 20–24] . However, 
only a few long-term studies have been performed, most-
ly in patients in methadone maintenance  [25, 26] . In ad-
dition, patients in studies of opioid agonists are hardly 
representative of the majority of opioid users and indi-
viduals with concurrent disorders are usually excluded 
 [27] . Previously, we reported the 1-year outcome of a 
large sample of opioid-dependent patients treated in var-
ious naturalistic outpatient settings in Germany provided 
by specialized substitution centres and office-based doc-
tors  [28] . Here, we report the long-term outcome (6 years) 
of these patients. 
 This prospective, longitudinal 6-year observational 
naturalistic study describes the course and outcome of 
patients in routine maintenance treatment in Germany. 
A random sample of patients was recruited at a nation-
ally representative sample of maintenance settings. The 
study addressed the following questions: (1) what is the 
6-year outcome in terms of retention, mortality and ab-
stinence (or transfer to abstinence treatment)? (2) What 
is the 6-year outcome in terms of the reduction of con-
comitant drug use and improvement of patients’ somatic 
and mental health status?
 Methods 
 Design 
 Details of the study and the 1-year outcome have been reported 
in detail elsewhere  [19, 24, 28, 29] . In brief, this was an observa-
tional 6-year prospective longitudinal study in an unselected prev-
alence sample of patients in maintenance treatment at a nationally 
representative sample of all substitution doctors in Germany  [24, 
28] . The study included a comprehensive baseline and a 12- and 
72-month follow-up. Assessments consisted of a self-report pa-
tient questionnaire, urine tests and a comprehensive clinical inter-
view and treatment documentation by the treating doctor. 
 Participants 
 Initially, a random sample of 379 doctors from a nationwide 
register of over 2,500 licensed and registered doctors qualified to 
conduct opioid maintenance therapy was invited to participate in 
the study; 223 agreed to participate (response rate: 58.8%). The 
sample was stratified to include a sufficiently high number of dif-
ferent settings and their patients. Settings ranged from office-
based, mostly primary care settings, to office-based doctors to 
large-scale, specialized substitution centres. For further details, see 
Wittchen et al.  [24, 28] .
 At baseline, a total of  n = 2,694 patients were enrolled from 
these 223 settings. The total baseline response rate of all eligible 
patients was 71.7%. The enrolment and all assessment procedures 
were checked by external monitors, for example, by comparing the 
initial list of all patient characteristics with those on the patient as-
sessment forms. 
 All patients aged at least 16 years with current opioid depen-
dence who were currently in agonist maintenance therapy with 
either buprenorphine or methadone were eligible for the study. 
Exclusion criteria included acute medical emergencies ( n = 11 ex-
cluded), cognitive impairments severe enough to compromise 
meaningful completion of the self-report forms ( n = 21), un-
willingness to comply with study procedures, including the man-
datory urine tests ( n = 17), and not being fluent in German (exact 
 n is unknown, but only very few participants were excluded for this 
reason). Each patient gave written informed consent and the study 
protocol was approved by the Ethics Committee of the Medical 
Faculty, Technische Universität Dresden, Germany.
 Follow-Up, Reasons for Non-Participation and Drop Out 
 Figure 1 describes the flow of the original  n = 2,694 patients 
from baseline through the follow-up periods and the respective 
intermediate assessments. A total of  n = 45 doctors who had 
been treating  n = 471 patients were not available at the second 
follow-up (T3; 3 doctors had died, 14 settings had been resolved 
and 28 doctors had discontinued their study participation for 
various reasons); however, we found 61 of the patients from 
these 45 doctors in other medical practices. Thus, information 
was documented for  n = 2,284 patients (conditional response 
rate: 71.1%). Of these 2,284 patients,  n = 1,624 were assessed for 
outcome at the final comprehensive 72-month follow-up inves-
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tigation (T3);  n = 660 patients were lost to follow-up between T2 
(12-month follow-up) and T3, as follows:  n = 80 patients discon-
tinued treatment within the observation period because of 
changes of residence, imprisonment for longer periods of time 
or changes in maintenance treatment (change in doctor or type 
of substitution drug); the treating doctor decided to discontinue 
maintenance therapy for an additional  n = 6 patients for disci-
plinary reasons, mostly because of serious concomitant drug 
use; and  n = 574 of the patients were not assessed at some point 
during the 72-month period for various other reasons. In total, 
 n = 1,070 patients were lost to follow-up during the 72-month 
observation period.
 Among the patients assessed for outcome at the final follow-up 
( n = 1,624), 1,147 patients had full outcome information, 346 had 
primary outcome information only and 131 patients had died (one 
additional patient was treated with codeine, for details on mortal-
ity see  [19] ). Among the  n = 1,493 patients alive and assessed for 
outcome at T3,  n = 1,216 were treated with methadone,  n = 270 
with buprenorphine and  n = 7 with other drugs (not further dealt 
with in this paper). Of the 1,147 patients will full outcome informa-
tion, 208 patients completed the maintenance treatment within the 
observation period, either because they became “clean” (i.e., suc-
cessfully terminated treatment) or because they were referred to an 
abstinence treatment setting. Additional interviews with doctors 
were conducted when necessary to ascertain patients “abstinence” 
status (see outcome criteria). 
 The analyses reported in this paper are thus based on  n = 1,493 
patients for whom follow-up and course information was ob-
tained. Separate analyses were also performed for the  n = 1,147 
patients who were still in treatment at the 72-month follow-up as-
sessment (i.e., excluding those who were not retained in treatment, 
had died or became abstinent) for whom complete baseline and 
follow-up documentation were available.
 Assessment 
 The patient questionnaire consisted largely of various compo-
nents of established instruments such as item groups of the 
 European Addiction Severity Index (EuropASI)  [30] and modules 
of the substance use questions of the WHO Composite Interna-
tional Diagnostic Interview (CIDI)  [31] . The patient questionnaire 
covered the following domains: (i) basic biosocial and socio-de-
mographic information, (ii) social and legal life developmental 
history and status ratings, (iii) past and current drug use and illness 
history module (CIDI), (iv) mental health and substance use diag-
nostic status (DSM-IV substance use and other mental disorders 
by CIDI), (v) self-reported physical disorders (e.g., hepatitis C, 
HIV), (vi) past and current social role impairments, disabilities 
and problems specific to drug use, (vii) past and current treatment 
history, (viii) met and unmet subjective needs, (ix) current and 
past experiences with treatments, (x) quality of life  [32] and (xi) 
risk behaviours (e.g., needle sharing, unprotected sexual behav-
iour). 
 Fig. 1. Flow diagram of patients. 
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Eligible settings: 194/223
Eligible patients:  2,442/2,694
Patients died: 28/2,442
Full assessment: 1,615/2,442
Partial** inform: 827/2,442
* Wittchen et al. DAD (2008)
** From monthly intermediate
course inquiries
Eligibility at T3:
Doctor died:   3    (34 patients)
Settings resolved:  14 (111 patients)
Doctor refused: 28 (326 patients)
Total:  45 (471 patients)
Note: A total of 61 of these patients
became eligible again (i.e. move to
eligible setting/replacement of doctor
Eligible T3 settings: 178/223
Eligible T3 patients:  2,223/2,694
Plus 61 patients who became eligible
Enrollment T3 (1/2008)
Primary outcome only:* 346 (21.3%)
Full outcome: 1,147 (70.6%)
Patients died/mortality assessment: 131 (8.1%)
Total assessed: 1,624 (71.1%)
* Due to unavailability of patient (e.g. living
abroad, institutionalized) or lack of doctor
assessment (no contact, abstinent)
Assessed for outcome T3: 1,624/2,284 patients
Doctor setting refused: 7 patients
Patient refused:  49 patients
Patients institutionalized: 39 patients
Patient status T3 unclear: 565 patients
Total not assessed T3  660 patients*
* Limited outcome information available for
470 of these patients for period T1/1 up to T3
Lost in follow-up period (no definite outcome)
T2 (12 monthS follow-up)*
Final T3
sample
Follow-up
(n = 2,284; 100%)
Eligible baseline (T1) sample n = 2,694 patients
sampled from n = 223 settings (2003/4)
Analysis
 Soyka/Strehle/Rehm/Bühringer/Wittchen Eur Addict Res 2017;23:97–105
DOI: 10.1159/000468518
100
 Clinical Interview and Assessment 
 The doctor evaluated each patient with a standardized inter-
view and appraisal that covered (i) current and past maintenance 
treatments along with documentation of onset and interruption of 
all lifetime treatment episodes (e.g., dosage, dosing status), (ii) lic-
it and illicit substance use behaviours and substance use, including 
severity ratings, (iii) past and current physical and mental disor-
ders, the severity of which was rated with the Clinical Global 
 Impression scale  [33] , and current and past treatments (e.g., men-
tal and selected somatic disorders, e.g., HCV and HIV status), (iv) 
multidimensional evaluation of social and psychological function-
ing, (v) past and current maintenance-related interventions, (vi) 
compliance and problems of management, (vii) individual treat-
ment targets, (viii) an abbreviated EuropASI rating to assess treat-
ment needs and (ix) ratings of health risk behaviours (needle shar-
ing, etc.). No formal training was provided for the EuropASI ad-
ministration.
 Urine Drug Screens 
 All patients underwent standardized urine drug screenings, su-
pervised by a nurse, at baseline and all follow-ups. Drug screening 
tools were provided by the study centre (certified Elisa test, immu-
nochromatography, test-kit Drug screen Multi 10; von Minden 
GmbH, Germany). Screening was performed for methadone, bu-
prenorphine, other opiates, cocaine, amphetamines, methamphet-
amines, benzodiazepines and cannabis.
 Measures 
 Retention was defined as the number of weeks that elapsed be-
tween study entry and the last week in opioid maintenance treat-
ment assessed at 3-month intervals. Retention rates were calcu-
lated for the total sample without those who had become abstinent. 
Mortality was defined as any death occurring during the follow-up 
period and after study entry, irrespective of the cause of death. Ab-
stinence/abstinence treatment was defined as successful discon-
tinuation of maintenance treatment by the doctor, either because 
the patient was considered to be clean (no positive opiate urine 
screens for 4 weeks) or because of change to abstinence treatments. 
Information about abstinence was based on the treating doctor’s 
rating in the follow-up interviews and a negative urine test, with-
out consideration of whether treatment was continued or discon-
tinued. Additionally, separate telephone interviews were conduct-
ed with these doctors 2–4 months later to confirm whether patients 
were still abstinent. Only patients who were confirmed to be still 
abstinent at this 2nd interview were counted as abstinent. Con-
comitant drug use was defined as a positive urine sample on the 
day of the personal examination (baseline and follow-ups). Any 
positive screening for non-prescribed opiates (methadone, bu-
prenorphine, others such as codeine), cannabis, cocaine, metham-
phetamine, amphetamine, benzodiazepine and hallucinogens was 
counted. The presence of methadone in buprenorphine patients 
was counted as concomitant drug use and vice versa. Somatic 
health and mental health were defined as the presence of clinician-
rated ICD-10 diagnoses of 9 explicitly described groups of somat-
ic disorders (e.g., cardiovascular conditions, liver diseases) with an 
open entry question, and 12 groups of mental disorders. Doctors 
were encouraged to code all applicable diagnoses definitely present 
during the past 12 months. In addition, the Brief Symptom Inven-
tory (BSI) total score was used to evaluate changes between base-
line and follow-up in the past week self-reported psychopathology.
 Statistical Procedures 
 We used multiple imputation with chained equations and ap-
plied the procedure ICE in Stata, version 12.1. Twenty imputed 
data sets were created with a total of 324 imputed variables (239 
from T3 and 85 auxiliary variables from prior assessments) related 
to substitution, treatment, morbidity and socio-demographic sta-
tus. The variables were sorted in ascending order by the fraction of 
missing data and filled by regressing on the respective chosen pre-
dictors. This procedure was cycled 10 times over all variables to 
achieve convergence.
 For the 1,147 patients who had full outcome data at T3, 
data  imputation was first based on 13 core predictors with 
few missing values (education, age, professional and education-
al status, substitution status, number of substitution drugs, 
 duration of maintenance treatment, ASI severity index, BSI 
 severity index; if necessary, these were in turn imputed by using 
the remaining variables and pre-measurements of the respective 
variables as predictors). Then we added pre-measurements of 
the respective variable and other measures from either the 
 doctor or the patient taken from similar domains (e.g., mental 
problems and physical diseases used to predict mental prob-
lems) that predicted the respective variable. Among the included 
variables, a backward selection was conducted if necessary 
(too few cases, empty cells, collinearity) to obtain more stable 
predictions. For each imputed variable, the regression model 
was chosen in accordance with the distribution of that variable 
(linear, logistic, cumulative logistic, negative binomial regres-
sion).
 For 346 patients, information only on the primary out-
come  variables was available. Consequently, multiple imputa-
tion by chained equations could not be performed because it 
would have resulted in the missing values being replaced by 
the  overall mean values. The selected variables of the doctor 
questionnaire and patient self-report as reported above were 
 imputed by a regression approach that included the following 
predictor variables: age, gender, professional status, family sta-
tus, type of substitution at T0 and T3, years of opiate use, years 
since first maintenance treatment and number of months of 
 current maintenance treatment. Additionally, mental and so-
matic diseases at T3 were also predicted by the disease status at 
T0.
 The variables observed at T0 predicted the T3 variables, includ-
ing missing values, by logistic regression models for categorical 
variables and by linear regression models for dimensional vari-
ables. The few missing values in the T0 predictor variables were 
imputed by their mean values.
 Results 
 Socio-Demographic and Selected Clinical 
Characteristics of the Study Sample 
 Table 1 presents the baseline demographics and select-
ed structured clinical interview information for the total 
sample. 
 Full outcome at T3 was reported for 1,147 patients and 
primary outcome only for 346 patients. 
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 Discontinuation, Death and Abstinence in the Total 
Sample and by Provider Setting 
 Overall, at the end of the 6-year observation period, 
1,144 out of 1,493 (76.6%) patients with primary or full 
outcome data were retained in treatment and 349 out of 
11,493 (23.4%) were no longer in maintenance treat-
ment. Among these 349 patients, 140 of 1,493 (9.4%) 
were opiate free (abstinent), 28 out of 1,493 (1.9%) were 
currently in inpatient treatment, 15 out of 1,493 (1.0%) 
in prison and 124 out of 1,493 (8.3%) had an unclear out-
come.
 747 out of 1,493 (50.0%) had a stable outcome in main-
tenance treatment, 207 out of 1,493 (13.9%) an unstable 
outcome (on and off, change of treatment setting).
 Changes in Concomitant Drug Use, Somatic and 
Mental Health 
 The Europ-ASI and BSI scores ( Table 2 ) indicated a sig-
nificant improvement of all domains assessed over time. 
The data on concomitant drug use indicated a significant 
improvement of drug intake (opioid use) from baseline 
(T0) to the 72-month follow-up (T3, see  Table 2 ). The urine 
Table 1.  Sociodemographic and clinical characteristics of patients
Number or mean 
(refers to all 1,4931, 2)
%/SD
Women 487 32.6
Men 1,006 67.4
Age, years 39.4 8.1
Occupation
Employed 527 35.3
Unemployed 631 42.3
Student at school or in higher education, apprentice, 
househusband/-wife, in early retirement 208 14.0
Other, retraining, work project 125 8.4
Marital status
Single 798 53.5
Married 198 13.3
Living apart, divorced, widowed 301 20.2
Other 195 13.0
Living situation
Living independently 1,430 95.5
Alone 821 55.0
With partner 495 33.1
With parents 176 11.8
Number of children
0 children 320 21.4
1 child 652 43.7
2 children 349 23.4
3+ children 171 11.5
BMI 25.2 5.9
Substitution substance
Methadone 1,216 81.4
Buprenorphine 270 18.1
Codeine 7 0.5
Mean years of opiate use 19.9 5.2
Mean years since 1st maintenance treatment 5.7 5.2
Mean number of maintenance treatments 2.3 1.5
Mean number of months of current maintenance 
treatment 19.5 8.2
 1 All participants alive and assessed for outcome at T3.
2 The summed n values may be higher because of rounding of imputed values.
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findings indicated that benzodiazepine use was underre-
ported and that about 20% of patients were using benzodi-
azepines at T1 and T3. Alcohol and cannabis use was more 
frequently reported and increased over time, while urine 
testing suggested a decline for cannabis (and cocaine) use.
 Discussion 
 Opioid dependence is a global problem that causes nu-
merous social, medical and legal problems  [5, 7, 11, 12] . 
Although psychotherapy and psychosocial treatment are 
effective in substance use disorders  [34], opioid mainte-
nance therapy is a well-established first-line treatment and 
widely used for opioid dependence  [16, 23] and is recom-
mended by numerous treatment guidelines  [10, 18, 35–37] . 
 The findings from this large, nationally representative 
sample of opioid-dependent patients underline the effec-
tiveness of opioid maintenance treatments with metha-
done and buprenorphine. Overall and most importantly, 
the data from this long-term follow-up indicate a high re-
tention rate, with over 70% of patients still in treatment 
after 6 years – most in stable maintenance treatment – and 
a rather low rate of opioid-abstinent patients (about 9%). 
While reported opioid use clearly decreased, cannabis and 
cocaine use increased over time, although urine testing for 
drugs suggested a decline. Probably many individuals 
used these drugs only sporadically and not continuously, 
as reflected by the toxicological data. Benzodiazepine use 
was underreported and remained stable over time; urine 
testing indicated that about 20% of participants were us-
ing benzodiazepines. Polydrug use remains a major con-
Table 2.  Comparison of BSI scores and concomitant drug use at T0 (baseline) and T3 (60-month follow-up)
T0 T3 T3 vs. T0
number or 
mean
% or SD number or 
mean
% or SD OR or MD 95 % CI p value
BSI
GSI 0.71 0.54 0.61 0.51 –0.10 –0.13 –0.07 0.000
Concomitant drug use
Alcohol, any use or alcohol to 
the point of intoxication 521 34.9 844 56.6 1.54 1.17 2.02 0.002
Cocaine 216 14.5 505 33.8 1.55 1.06 2.28 0.025
Opiates 252 16.9 78 5.2 1.15 0.56 2.35 0.699
Methamphetamine 14 0.9 25 1.7 –
Methadone 221 14.8 50 3.3 0.76 0.21 2.76 0.681
Amphetamines 125 8.4 9 0.6 2.64 0.22 31.97 0.446
Codeine 26 1.7 142 9.5 0.79 0.13 4.82 0.799
Benzodiazepine 181 12.1 34 2.3 1.07 0.29 3.88 0.920
Buprenorphine – 47 3.2 –
Cannabis 426 28.5 546 36.6 1.20 0.89 1.62 0.234
Hallucinogens 520 34.8 973 65.2 1.66 1.20 2.29 0.002
Urine screening
Amphetamines 18 1.23 25 1.66 12.93 1.07 156.63 0.044
Benzodiazepines 313 20.99 289 19.40 6.24 4.33 8.99 0.000
Methadone 1,140 76.15 1,220 81.94 12.55 9.22 17.07 0.000
Methamphetamine 15 0.99 44 2.98 –
Cocaine 124 8.28 48 3.20 5.72 2.34 13.99 0.000
Opiates 292 19.55 184 12.35 3.03 2.04 4.49 0.000
Cannabis 645 43.25 495 33.16 4.61 3.49 6.10 0.000
Buprenorphine 286 19.20 –
TCA 180 12.06 –
Sleeping pills and tranquilisers 18 1.22 –
Hallucinogens 18 1.22 –
Codeine 74 4.96 –
GSI, global indicator; TCA, tricyclic antidepressants; BSI, brief symptom inventory.
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cern in these patients. The relatively high number of indi-
viduals with alcohol use found in this study corresponds 
to similar findings in other studies (for review see  [38] ).
 This cohort still had a significant mortality rate, which 
did not decline substantially over time  [19] , but it was 
lower than usually found in opioid-dependent patients. 
In comparison to findings from a meta-analysis by 
 Degenhardt et al.  [4], these data indicate comparably low 
mean crude annual mortality rates of 1.0% and 1.2 per 100 
patient years, probably reflecting the beneficial effect of 
opioid maintenance treatment.
 Somatic and psychiatric comorbidity showed some 
improvement, but many patients still had a significant 
number of other medical or psychiatric disorders over the 
course of the study. In general, there is substantial clinical 
evidence that opioid maintenance treatment has proven 
efficacy in reducing opioid consumption, psychosocial 
and medical morbidity and in increasing treatment reten-
tion rates and social functioning in opioid addicts also in 
the long run  [16, 23] .
 In line with findings from previous clinical studies  [20, 
24] , our data, which cover a longer time period than most 
studies, demonstrate low mortality rates of about 1% and 
a relatively high 6-year retention in treatment of about 
70%. Noteworthy is that a similar mortality rate was re-
cently reported in a 4.5-year (mean) follow-up study of 
patients who had been randomized in an opioid treat-
ment programme to receive open-label methadone or bu-
prenorphine/naloxone  [26] . Furthermore, Evans et al. 
 [39] found a 3.2% mortality rate in 32,322 individuals in 
pharmacological treatment over a 2.6-year (mean) treat-
ment period; mortality was highest when individuals 
were out of treatment and during detoxification, particu-
larly in the 2-weeks post-treatment entry. Degenhardt et 
al.  [40] estimated the mortality reduction in opioid main-
tenance therapy to be 29%.
 Although a number of long-term studies have been 
performed in opioid-dependent individuals  [41, 42] and 
numerous short-term clinical and experimental studies 
have examined the efficacy of opioid maintenance thera-
py  [16, 23] , relatively few studies have studied opioid-de-
pendent patients in opioid maintenance treatment over 
long time periods. Fifteen-year follow-up data from a 
small group of Swedish methadone patients indicate that 
an opiate-free life can be achieved  [43] , but most studies 
agree that opioid-dependent patients with and without 
maintenance therapy have a high risk for inpatient treat-
ments and detoxification  [44] . An important 15-year fol-
low-up of an Israeli sample ( n = 613), published by Peles 
et al.  [6] , found that patients staying longer in treatment 
had a lower mortality rate. Predictors of survival were un-
der 40 years of age at admission, living with a partner, be-
ing hepatitis B sera-negative, no benzodiazepine abuse, 
being referred from hospital to maintenance treatment 
and not leaving treatment for hospitalization. The last 
2 variables also predicted longer retention and no opioid 
and benzodiazepine abuse, among others. In this study, 
no psychiatric diagnosis was a positive predictor, while 
Maremmani et al.  [45, 46] found the opposite result. A 
4.5 years’ prospective study in Macao also showed a high 
long-term retention of patients in opioid maintenance 
therapy  [47] . An interesting registry-based study for 
methadone programs was published by Huissoud et al. 
 [48] . The probability of remaining on treatment was 69% 
at 1 year and 45% at 3 years ( n = 1666). Data from Cana-
da indicate that long-term retention over 36 months is 
achieved only in 20–25% of all patients in methadone 
treatment, while 12-month retention figures fell from 
45.9% in 2001 to 40.5% in 2005  [49] .
 The strengths of our study are its reliance on a large na-
tionally representative and heterogeneous sample of 
maintenance treatment providers and a random sample of 
their patients, the 6-year duration of the observation pe-
riod and the coverage of a wide range of variables describ-
ing course and outcome, including urine drug tests. In ad-
dition, relevant follow-up information was available for a 
majority of patients even after about 6 years. Noteworthy 
limitations of the study are that it was a strictly observa-
tional, naturalistic study and not a randomized control 
group design. Thus, causal inferences are not possible and 
any causal conclusions regarding the effects of different 
treatments and settings need to be interpreted with cau-
tion. Further limitations are as follows: (i) initially, only 
59% of eligible settings participated and no information is 
available whether non-participating settings differed from 
those that participated [see  24] ; (ii) patients not fluent in 
German were excluded from the study because of the as-
sessment instruments, so we could not assess whether pa-
tients with a migration background have a worse outcome 
than those included in this study; (iii) no formal interviews 
with standardized psychiatric assessment instruments 
could be used in this study; and (iv) data on somatic co-
morbidity (HIV, hepatitis) were collected on the basis of 
clinical and interview data and no formal screening or test-
ing was performed at T3 (6-year follow-up). Our outcome 
data basically rely on interviews with treating doctors and 
patients and additional data on psychiatric outcome could 
help to further elucidate predictors of outcome. 
 Taking into account these limitations, this study pro-
vides several basic findings:
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 (1)  The retention rate in routine care is relatively high, 
also in the long term. 
(2)  The annual mortality rate is lower than those usually 
found in untreated populations. 
(3)  The overall level of psychiatric and somatic symptoms 
decreases over time. 
(4)  Opioid abstinence is possible, but rather rare. 
 Future studies may especially address individuals with 
a less favourable outcome and strategies to optimize tran-
sition into drug-free living.
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